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The overall redox potential of a cell is primarily determined by oxidizable/reducible chemical pairs, in-
cluding glutathione–glutathione disulﬁde, reduced thioredoxin–oxidized thioredoxin, and NADþ–NADH
(and NADP–NADPH). Current methods for evaluating oxidative stress rely on detecting levels of in-
dividual byproducts of oxidative damage or by determining the total levels or activity of individual
antioxidant enzymes. Oxidation–reduction potential (ORP), on the other hand, is an integrated, com-
prehensive measure of the balance between total (known and unknown) pro-oxidant and antioxidant
components in a biological system. Much emphasis has been placed on the role of oxidative stress in
chronic diseases, such as Alzheimer's disease and atherosclerosis. The role of oxidative stress in acute
diseases often seen in the emergency room and intensive care unit is considerable. New tools for the
rapid, inexpensive measurement of both redox potential and total redox capacity should aid in in-
troducing a new body of literature on the role of oxidative stress in acute illness and how to screen and
monitor for potentially beneﬁcial pharmacologic agents.
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The change in the Gibbs free energy (ΔG) of a chemical reac-
tion can be described in terms of the equilibrium constant of theB.V. This is an open access article u
auma Research Department,
CO 80113, USA.
ar-Or),
arma.com (L.T. Rael),reaction and the electromotive force of each half reaction under
standard conditions. This electromotive force is simply the ten-
dency of each half reaction to lose or gain electrons. Another name
for theΔG of a reaction is the redox potential. Such measurements
have been documented for many isolated biochemical reactions
and constitute part of our understanding of biological chemistry,
analogous to the way the measurement of pH has led to an un-
derstanding of Hþ ions in biology. Because human cells derive
energy using electron transfer from donor species to oxygen, andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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enzymatic activity of many proteins also depend on the redox
potential of the cellular environment, an understanding how this
milieu changes in certain disease states is of great interest.
The overall redox potential of a cell is primarily determined by
oxidizable/reducible chemical pairs, including glutathione–glu-
tathione disulﬁde, reduced thioredoxin–oxidized thioredoxin, and
NADþ–NADH (and NADP–NADPH). There are, nonetheless, some
areas of heterogeneity with respect to redox potential inside the
cell. In particular, whereas the overall ratio of reduced to oxidized
glutathione in a cell is less than 30:1 (and usually at least 100:1),
this does not seem to be true for the endoplasmic reticulum,
where this ratio has been reported to range from 1:1 to 3:1 [1].
This difference is remarkable as the endoplasmic reticulum is
precisely the cellular compartment in which correct disulﬁde lin-
kages (oxidation) must be formed in proteins as they are synthe-
sized in order for them to be active. James Watson has argued that
imposing too many anti-oxidants on an organism could lead to
poor protein folding because the redox potential might be too low
for correct disulﬁde bond formation [2].
In addition, the major anti-oxidant mechanisms, as well as the
overall manner of generating reactive oxygen species, vary a great
deal between the intra-cellular and extra-cellular milieu [3]. For
example, reduced glutathione is the major intra-cellular thiol
compound (between 3 and 10 mM) whereas this compound is
about 1000-fold less concentrated in extra-cellular ﬂuid (about
2.8 mM). The extra-cellular ﬂuid possesses cysteine as its major
thiol compound [4]. There are three superoxide dismutases (SOD),
one mitochondrial, one intra-cellular (but not in the mitochon-
dria), and one extracellular. The three have different properties but
all catalyze the same reactions, eliminating the superoxide anion
and producing molecular oxygen and hydrogen peroxide (which is
then removed by catalase). Despite the differences in extra-cellular
and intra-cellular mechanisms of free radical generation and re-
moval, the two systems are in a general equilibrium, with most of
the free radicals being generated intra-cellularly, especially in
mitochondria, while most of the measurements cited here of
oxidative stress in severe acute disease are of extra-cellular ﬂuids,
especially serum/plasma.
The utility of knowing the redox potentials of biological ﬂuids
exists on two levels. First, the overall measure of the redox po-
tential in a biological ﬂuid, such as blood, urine, or cerebrospinal
ﬂuid (CSF), is a result of the myriads of reactions (glutathione
synthesis, glutathione oxidation, NADþ and NADP reduction,
thioredoxin regeneration and synthesis, nutrition, pathological
processes, etc.). The combination of these reactions provides a
single redox potential, which is measured in millivolts. Multiple
studies have shown that this measurement can be useful in eval-
uating acute diseases, such as traumatic brain injury, severe sepsis,
stroke, and myocardial infarction, as well as chronic diseases, such
as Alzheimer's disease and atherosclerosis. Redox potential was
predominantly used only as a research tool in the past, perhaps
because redox potential measurements were recorded on cum-
bersome devices that used large electrodes, required large vo-
lumes, produced slow readouts, and were not adapted to the easy
use and fast turnaround times required in an emergency room
(ER) or intensive care unit (ICU) setting. Current methods for
evaluating oxidative stress rely on detecting levels of individual
byproducts of oxidative damage or by determining the total levels
or activity of individual antioxidant enzymes. Oxidation–reduction
potential (ORP), on the other hand, is an integrated, comprehen-
sive measure of the balance between total (known and unknown)
pro-oxidant and antioxidant components in a biological system.
An ORP measurement that is signiﬁcantly higher than that of a
reference sample indicates the presence of oxidative stress. In the
clinical setting, assessment of ORP can provide a global measure ofthe redox status of a biological sample. Furthermore, assessing the
ORP of a biological sample does not rely on any individual marker.
Recent clinical studies in patients with traumatic brain injury
(TBI) and multiple trauma have shown the utility of ORP as an
indicator of redox status. A clinical study in patients with isolated
TBI demonstrated that ORP values from plasma were signiﬁcantly
elevated at the time of admission to the trauma center in patients
with mild-to-moderate isolated TBI compared with healthy in-
dividuals [5]. Consistent with ORP accurately reﬂecting redox
status, this study detected signiﬁcantly higher levels of oxidized
human serum albumin in patients with TBI compared with healthy
individuals. Additionally, a study of redox status in trauma patients
found that plasma ORP values were signiﬁcantly elevated in pa-
tients with severe trauma compared with healthy individuals [6].
Total levels and activity of the antioxidant paraoxonase–ar-
ylesterase were also reduced in these patients with severe trauma
compared with healthy individuals, indicating the presence of
oxidative stress. Furthermore, ORP values in the patients with
severe trauma approached normal levels by the time of discharge
following recovery. Importantly, a separate study reported that
plasma ORP levels in patients with moderate-to-severe trauma
correlated positively with the severity of injury [7]. Taken together,
these results demonstrate the potential for using ORP to assess
oxidative stress, severity of injury, and overall health status in
patients with TBI and severe trauma.
All published research on ORP monitoring in critical illness was
performed using a bench top ORP microelectrode suitable for a
research laboratory only. Therefore, after demonstrating that ORP
monitoring provides the clinician with valuable information on the
redox status in a patient, it became imperative that a point-of-care
device suitable for a clinical setting be developed.
Once the inﬂuence of redox potential has been established for a
disease process or therapeutic intervention, one can hone in on
the exact damage done to the tissue by various redox imbalances
and study their speciﬁc deleterious effects. Before we examine this
idea for speciﬁc clinical entities below, we ﬁrst review the types of
molecular insults generated by free radicals during oxidative
stress.
Nucleic acids
In biological systems, the ferric ion is reduced to the ferrous ion
by the superoxide free radical, generating oxygen. The ferrous ion
can then react with hydrogen peroxide, which itself is a product of
cell respiration, to produce the very reactive hydroxyl radical (the
Fenton reaction). The hydroxyl radical can further generate other
free radical species but also oxidizes the nucleotides in DNA and
RNA as well as the bases and sugars in mono-nucleosides and
mono-nucleotides. Although multiple products have been isolated
from damaged nucleic acids, the major products and most widely-
studied are 8-hydroxydeoxyguanosine in DNA and 8-hydro-
xyguanosine in RNA. In DNA, this base can be mutagenic and, thus,
carcinogenic in principle. Although less studied, the RNA base can
lead to accelerated degradation and a reduced capacity for protein
translation. A variety of DNA repair enzymes exist to remove oxi-
dized deoxyguanidine from DNA and thus eliminate its potential
mutagenicity. Perhaps more intriguing from the point of view of
acute illnesses is the fate of oxidized guanidine in RNA. RNA
miscoding or mRNA degradation are rapid events, rendering them
more signiﬁcant to acute disease development than the effects of
DNA mutation. Suggestions from the literature indicate RNA oxi-
dization leads to the binding of proteins that may either act as or
recruit nucleases to that site [8,9]. Further research into this pos-
sibility for acute diseases may be accomplished with an interesting
technology that was previously described for the global analysis of
RNA oxidation in Saccharomyces cerevisiae [10]. Here, the authors
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droxyguanosine residues and sequenced them, looking particu-
larly at the large number of mRNAs whose oxidized guanosine
residues were increased after a brief treatment of the yeast cells
with hydrogen peroxide. Such techniques could become available
for the cell types involved in various acute human diseases.
Lipids
Reactive oxygen species react with multiple, long-chain, un-
saturated fatty acids in cell membranes to generate lipid perox-
idation products, particularly malondialdehyde (MDA). These
products can then react with other functional groups, especially
amines, to generate another reactive aldehyde, 4-hydroxynonenal
(HNE), which has been well studied with respect to its down-
stream reactions [11]. The chemistry of both the damage done by
these free radical-generated compounds and their reduction by
anti-oxidants has been the subject of many reviews [12,13]. The
biological consequences of lipid peroxidation are primarily con-
cerned with membrane function [14]. For example, HNE is toxic to
neurons and impairs glutamate uptake as well as mitochondrial
function at synapses, leading to the excitotoxic death of the neu-
rons [15]. A factor that must be taken into account is the meta-
bolism of these oxidative compounds in various tissues. Recently,
for example, the lipid peroxidation product HNE was shown to be
rapidly degraded in the liver but almost not at all in the lung and
brain [16]. Thus, free radical generation would be expected to have
much more severe consequences in the lung and brain than in the
liver.
Proteins
Amino acids, both as free monomers and as the building blocks
of polypeptide chains, can be oxidized by free radicals to produce a
variety of compounds, including peroxides, keto-acids, and a large
number of derivatives. Protein oxidation can occur at the amino
group, the carboxyl group, or the various side chains that impart
each amino acid with its unique properties. In terms of causing
disease, such changes can induce enzyme inactivation, protein
degradation, altered binding properties, the faulty transport of
small molecules across membranes (a property shared with oxi-
dized lipids), and the oxidation of cysteine residues to cysteine
dimers through disulﬁde bonds for example. It has been suggested
that protein oxidation can facilitate ubiquitination, which then
targets these proteins for degradation by the proteasome [17]. In
addition, accumulated oxidized protein may play a role in aging,
although there is no direct evidence for this. Clearly, undegraded,
misfolded, and oxidized proteins can be causative agents in
chronic diseases, such as Alzheimer's disease and amyotrophic
lateral sclerosis (ALS), but it is not yet known if the protein ab-
normalities induced by reactive oxygen species are etiologic fac-
tors in acute diseases.Role of reactive oxygen species in acute disease
It is well established that any oxygen-consuming organism will
generate free radicals during respiration and such free radicals
interact with compounds in tissues to generate a variety of oxi-
dized species with a concomitant reduction of the oxidizing
compound. Many of these oxidized species are deleterious to tis-
sues and organs in humans, but not all have been thoroughly
studied. Of note, but which we have not discussed in this article, is
that there are anti-oxidant compounds, both generated by meta-
bolism and ingested as food and food supplements, which can
sometimes mitigate the deleterious effects of free radicalinteractions. Therefore, attempting to understand the role of free
radical damage in human disease is complicated by the ﬂux of
reactive species, which is inﬂuenced by the ﬂux of anti-oxidant
compound production and ingestion. Perhaps the best approach
for studying the role of oxidative stress in disease, then, is to ﬁrst
measure the overall redox capacity of the tissue and blood before
evaluating the effect of speciﬁc compounds.
Expending the known reduced species (NADHþ , reduced glu-
tathione, etc.) to “neutralize” the deleterious compounds weakens
the organism's capacity to combat further oxidative stress. Thus,
the easy measurement of the redox capacity, as well as the redox
potential, should not only help us to understand the current state
of the organism but should also be predictive and prognostic for
evolving diseases.
The role of continuing oxidative stress has been studied in a
variety of chronic diseases, including diabetes mellitus, Alzhei-
mer's disease, ALS, and atherosclerosis, but less attention has been
paid to the role of oxidative stress in the progression and prog-
nosis of acute disease. Next, we shall review four acute conditions
that are likely to be seen in the ER and ICU, and evaluate the
contribution of measuring redox potential in their management.
Traumatic brain injury (TBI)
The brain is vulnerable to injury by oxidative stress as its rate of
oxygen consumption is high, nerve cells are not easily replenished,
and the high levels of unsaturated fatty acids in the brain mem-
branes are targets of the lipid peroxidation reactions initiated by
reactive oxygen species. A seminal study in a pediatric setting
(trauma is the leading cause of death in children) compared CSF
from children aged two months to 16 years with severe TBI
(Glasgow Coma Scale r8) with the CSF from children undergoing
lumbar puncture to rule out a diagnosis of meningitis. The pre-
sence of a TBI led to a sustained reduction of the total anti-oxidant
reserve and a decrease in the levels of the anti-oxidants ascorbate
and reduced glutathione. In addition, there were increased levels
of lipid peroxidation products and protein oxidation [18]. More-
over, in a larger pediatric population, the amount of nerve damage,
as measured via the activity of neuron-speciﬁc enolase, was cor-
related with the level of the lipid peroxidation product F2-iso-
prostane after day 1 of TBI [19]. Reactive oxygen species also
promote the formation of peroxynitrite, which reacts with tyr-
osine to yield 3-nitrotyrosine. In an adult population, the oxidative
product nitrotyrosine was not detected in normal CSF. In severe
TBI, on the other hand, nitrotyrosine was present in most of the
CSF samples. Thus, the consistent presence of nitrotyrosine in CSF
samples from TBI patients has been suggested to be a prognostic
indicator of poor outcome [20]. Most recently, peroxiredoxin VI
has come to the forefront in the list of potential prognostic mar-
kers in TBI. Peroxiredoxin VI is a major anti-oxidant enzyme nor-
mally found in astrocytes. While this enzyme is present in the CSF
of both normal and TBI patients, its enzymatic activity is high in
the CSF of normal patients but is greatly diminished in the CSF of
TBI patients, signifying that the enzyme is oxidized after the
traumatic event. Signiﬁcantly, recovery of the enzymatic activity at
24 h after admission was shown to be a prognostic sign of re-
covery, whereas continued low enzymatic activity after 24 h was
shown to be a prognostic sign of poor outcome [21]. Thus, speciﬁc
oxidation products as well as total redox capacity are worth in-
vestigating in the search for biomarkers of successful treatments of
TBI in the near future.
Sepsis
Sepsis and the multiple organ failure often seen in response to
sepsis are the most common causes of death in the ICU. Oxidative
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of sepsis has been well documented, and oxidized species of lipids
and proteins are prominent in this disease state. Increased lipid
oxidation was observed in patients who presented with three or
more dysfunctional secondary organs compared to patients with
two or fewer dysfunctional secondary organs [22]. In septic pa-
tients, both plasma superoxide dismutase (SOD) and plasma cat-
alase are elevated compared to healthy normals. This difference is
expected because of the increased production of the superoxide
ion and hydrogen peroxide in septic patients. Plasma SOD is high
in non-survivors of sepsis but tends to decrease to about a third of
these high levels in survivors [23]. When total redox capacity is
measured in sepsis instead of individual free radicals or oxidized
cell components, a clear decrease is seen in septic patients com-
pared to healthy controls. This low redox capacity stays low in
patients who succumb to sepsis, whereas it tends to return to
normal in patients who survive the disease. Thus, one could
imagine that the total redox potential could measure the efﬁcacy
of treatment in severe sepsis [24]. Increased levels of xanthine
oxidase, SOD, and glutathione peroxidase were also seen in a pe-
diatric septic population, although no prognostic correlation with
outcome was observed [25]. More recently, emphasis has been
placed on the oxidative stress that occurs at the point of produc-
tion of most reactive oxygen radicals, namely the mitochondrion.
It has been suggested that mitochondrion-targeted anti-oxidant
therapy may be more effective for patients with sepsis or septic
shock than therapy with global anti-oxidant compounds [26].
Stroke
Before discussing the role of reactive oxygen species in stroke,
it is important to clarify an apparent paradox of free radical pro-
duction in tissues. This is especially pertinent to the discussion of
stroke but is also relevant for discussion of a number of diseases in
which tissues become hypoxic but free radical damage is invoked.
The superoxide anion and, subsequently, hydrogen peroxide are
produced in the mitochondria during respiration. In general, the
higher the oxygen partial pressure, the higher the production of
free radicals [27]. Paradoxically, when cells become hypoxic (for
example, in cultured cells when the ambient oxygen is reduced
from 21% to 1–3% oxygen), the production of reactive oxygen
species increases. This seems to be related to the stabilization of
hypoxia-inducible factor 1 (HIF 1) at low oxygen pressures. HIF 1 is
a transcription factor that induces the transcription of ery-
thropoietin, vascular endothelial growth factor (VEGF), and a
variety of other mRNAs, which re-adjusts the metabolism of the
cell. Through a mechanism that has not yet been elucidated, these
metabolic changes interact with the mitochondrial respiratory
chain to increase the release of the superoxide anion and hydrogen
peroxide from this chain [27–29].
Stroke accounts for 9% of deaths worldwide. The majority (80–
85%) of strokes are ischemic, in which a blood clot cuts off the
blood supply to a region of the brain. The other 15–20% are he-
morrhagic, in which a blood vessel bleeds into a region of the
brain, severely disturbing brain function. By measuring oxidative
stress via the serum MDA concentration and total redox capacity
via the level of free thiol groups in serum, a recent study showed
that reactive oxygen species were increased and total redox ca-
pacity decreased on days 1 and 7 after ischemic stroke [30]. In this
study, the highest MDA concentration and the lowest total redox
capacity were associated with poor outcome. Also, the MDA level
on day 7 after the stroke was reported to be an independent
predictive factor for three-month outcomes. The lipid peroxidation
product 8-isoprostane was elevated in the sera of patients who
had suffered an ischemic stroke. In this study, it was reported that
a statin, simvastatin, showed an anti-oxidative effect in inhibitingthe rise of 8-isoprostane [31]. In another study, 8-isoprostane was
elevated and the natural anti-oxidant vitamin C was lowered in
the blood of patients who had suffered an ischemic stroke; inter-
estingly, the decrease in vitamin C was proportional to the in-
crease in 8-isoprostane [32]. The demonstration that reactive
oxygen species play a role in the brain damage observed after an
ischemic stroke has led to the introduction of many anti-oxidants
as potential medicines to ameliorate outcomes.
Combination vitamin C and vitamin E therapies have been
evaluated for ischemic stroke patients in a number of settings, and
some suggestive positive results have been found [33,34]. A study
using B group vitamins has shown that inﬂammatory markers are
decreased after stroke, but no effect on clinical outcomes was re-
ported [35]. Oxidative stress is equally implicated in the other
group of stroke patients, those suffering from hemorrhagic
strokes. For instance, total superoxide dismutase levels were found
to be higher in brain samples from patients after sub-arachnoid
hemorrhages than in those with unruptured aneurysms [36].
Myocardial infarction
Myocardial infarction is caused by the lack of blood supply to
regions of heart muscle. The lack of blood supply is usually pre-
ceded by chronic atherosclerosis, diminishing blood supply, and,
thus, oxygen to the heart muscle. As mentioned above, this hy-
poxia leads to a paradoxical increase in reactive oxygen and ni-
trogen species. Moreover, once an infarct is treated, the reperfu-
sion to the damaged myocardium also leads to increased oxidative
stress [37,38]. The extent of myocardial damage and subsequent
clinical outcome seems to be related to the severity of the original
oxidative stress, and the anti-oxidative milieu brought to bear on
these reactive species. This is best illustrated in patients with
diabetes mellitus, who tend to have more severe atherosclerosis,
more frequent myocardial infarcts and worse outcomes from these
MI’s, than non-diabetic patients. This has been postulated to be
caused by the more severe oxidative stress in tissues of diabetics
than in others [39]. More recent evidence supports this idea.
Diabetic patients suffer twice the mortality after MI than do non-
diabetic patients, and this is correlated with increased levels of
Caþ þ–calmodulin dependent protein kinase II delta, which is
known to be involved in redox control [40]. In an experimental
rodent model, the increased mortality associated with diabetes
can be eliminated by using a “knock-in” technique rendering this
enzyme insensitive to oxidation (it is methionine oxidation which
causes the damage) [41]. Also in a rat model of diabetes, the
consequences of MI could be drastically reduced by using a cloned
thioredoxin-1 gene to express this enzyme to reduce oxidative
stress in heart muscle. This gene therapy reduced mortality by
increasing expression of thioredoxin-1 and heme oxygenase-1 as
well as of VEGF; this led to increased angiogenesis in the heart
muscle and decreased ventricular remodeling [42]. Such promis-
ing results have led to a clinical trial in human MI to test whether
the anti-oxidants Vitamins C and E might reduce the infarct size in
MI patients undergoing percutaneous coronary angioplasty. Vita-
min C will be given directly to heart muscle and Vitamin E will be
given orally. This trial should be fully enrolled in 2016 [43].
Quite recently, a study has been published which probably
exempliﬁes all of the points we have tried to make here. In heart
muscle (as well as in other organs), Chouchani et al. showed that
ischemic changes included a cytosolic change in xanthine oxido-
reductase, which does not inﬂuence mitochondrial reactive oxy-
gen species, and a huge increase in succinate, which is an inter-
mediate in the mitochondrial citric acid cycle [44]. They went on
to show that this hypoxic change was induced by formation of
succinate from fumarate by a reversal of the succinate dehy-
drogenase enzyme. When reperfusion occurred the succinate
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thus ischemia–reperfusion injury in the heart muscle. They
showed that dimethylmalonate, a precursor to malonate, which
inhibits succinate dehydrogenase, leads to a reduction in ische-
mia–reperfusion injury. This seems to be a clear demonstration
that mitochondrial production of reactive oxygen species leads to
at least some of the extra-cellular injury associated with MI.
Multiple trauma
Reactive oxygen species and oxidative stress are also associated
with many other acute diseases likely to be seen in the ER or ICU.
These include multiple trauma cases and burn patients. For ex-
ample, increased levels of lipid oxidation products have been ob-
served in patients undergoing cardio-pulmonary bypass while
their circulation and blood oxygenation are extra-corporeal [45].
In patients with extensive burns, the plasma levels of the anti-
oxidants vitamin E and retinol are decreased at admission but are
increased over time during recovery [46]. Many of these ﬁndings
suggest that common pathways of reactive oxygen species pro-
duction and common biochemical targets of these species may be
present in multiple organs. For example, endothelial stem cells
and polymorphonucleated leukocytes (PMNLs) accumulate at
trauma sites of all varieties. Trauma-activated PMNLs produce re-
active oxygen species, which kill the stem cells, and this may be a
common mechanism of organ failure in trauma and burn patients
[47].Conclusion
Research on reactive oxygen species and their role in disease
causation has taken parallel paths. On the one hand, the enu-
meration of all oxidized products, including those resulting from
nitrogen-free radical compounds, has been more or less divorced
from the identiﬁcation of speciﬁc pathways for speciﬁc diseases.
Those studying diseases in which reactive oxygen species play at
least a partial etiologic role tend not to characterize all of the re-
sponsible species nor focus on speciﬁc pathways. In many ways,
this is understandable because both undertakings are enormous,
as is the pharmacologic search for reducing agents that may help
to ﬁght some of these diseases. Much emphasis has been placed on
the role of oxidative stress in chronic diseases, such as Alzheimer's
disease and atherosclerosis, but as we have shown here, the role of
oxidative stress in severe acute diseases often seen in the ER and
ICU is considerable. Moreover, the pharmacologic effort to identify
compounds that can relieve oxidative stress in acute illness is
likely to be somewhat different than the therapeutic compounds
that are successful in ﬁghting chronic disease. New tools for the
rapid, inexpensive measurement of both redox potential and total
redox capacity should aid in introducing a new body of literature
on the role of oxidative stress in acute illness and how to screen
for potentially beneﬁcial pharmacologic agents.References
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